Physician profile
Daniel M Kim
NPI 1548648868
$8,632.34
in general payments reported to CMS, 2019-2025
35 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $380 · 2023: $2,482 · 2024: $2,659 · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,132.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,775.97 | 2022-2025 | |
| Janssen Biotech, INC. | $870.41 | 2023-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $759.95 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $439.85 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.84 | 2022-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $357.97 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $350.09 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $303.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $280.87 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $178.67 | 2023-2025 | Dupixent |
| Enterra Medical, INC. | $171.13 | 2023 | |
| Phathom Pharmaceuticals, INC. | $167.43 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $149.80 | 2025 | Omvoh |
| Motiva USA, LLC | $149.35 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $139.64 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $136.45 | 2022-2025 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $120.08 | 2021 | |
| Gilead Sciences, INC. | $114.48 | 2024-2025 | |
| Pfizer INC. | $114.09 | 2025 | |
| Sientra, INC. | $88.58 | 2022 | |
| Intercept Pharmaceuticals, INC. | $79.83 | 2023-2025 | Ocaliva |
| Integra Lifesciences Corporation | $71.27 | 2023-2024 | Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template |
| Fresenius Kabi USA, LLC | $60.10 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $56.78 | 2023-2025 | Rebyota, Clenpiq |
| Qol Medical, LLC | $45.46 | 2025 | Sucraid |
| Vivus LLC | $41.41 | 2025 | Qsymia, Pancreaze |
| Albireo Pharma, INC. | $35.78 | 2024 | Iqirvo |
| Ipsen Biopharmaceuticals, INC | $33.19 | 2025 | Iqirvo |
| Boston Scientific Corporation | $28.14 | 2024 | |
| Medtronic, INC. | $27.45 | 2023 | Manoscan |
| Biocon Biologics INC | $27.34 | 2025 | Hulio |
| Lucid Diagnostics INC. | $21.55 | 2022 | |
| Daiichi Sankyo INC. | $20.73 | 2022 | |
| Exact Sciences Corporation | $17.21 | 2023 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $15.46 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.